Onco Wiki / Rote Flagge

ROS1-Fusion (CD74-ROS1, EZR-ROs1, andere) — ~1-2 % des NSCLC-Adenokarzinoms; nie rauchen...

Deterministische Ansicht der Quelle YAML Entität. Klinische Autorität bleibt mit den zitierten Quell-IDs und Rezensenten Sign-off Zustand.

IDRF-NSCLC-ROS1-FUSION-ACTIONABLE
ArtWarnhinweis
Statusreviewed 2026-04-27 | pending_clinical_signoff
ErkrankungenDIS-NSCLC
QuellenSRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 SRC-STARTRK2-DRILON-2020 SRC-TRIDENT1-DRILON-2024

Ursprung der Roten Flagge

BegriffsbestimmungROS1 fusion (CD74-ROS1, EZR-ROS1, others) — ~1-2% of NSCLC adenocarcinoma; never-smoker enriched. Treatment-defining: entrectinib (CNS-active) or repotrectinib (TRIDENT-1, including post-crizotinib resistance) preferred 1L; crizotinib historic option.
Klinische RichtungIntensivierung
Kategoriehigh-risk-biology
Schaltet AlgorithmusALGO-NSCLC-METASTATIC-1L, ALGO-NSCLC-METASTATIC-2L

Logik auslösen

{
  "any_of": [
    {
      "finding": "ros1_fusion",
      "value": true
    },
    {
      "finding": "ros1_rearrangement",
      "value": "positive"
    },
    {
      "finding": "ros1_status",
      "value": "positive"
    }
  ],
  "type": "biomarker"
}

Anmerkungen

Detection: RNA-NGS preferred for fusion partner; IHC screen with ROS1 antibody (D4D6) acceptable. Repotrectinib next-gen TKI active vs solvent-front G2032R resistance mutation; preferred 1L+ in guidelines updated post-TRIDENT-1. Brain metastases — entrectinib and repotrectinib have CNS activity; crizotinib does not.

Verwendet von

Algorithmen